L-Ornithine-L-Aspartate (LOLA) is indicated for the treatment of hyperammonemia, particularly in patients with liver dysfunction, including hepatic encephalopathy. Its key advantage is a targeted mechanism that enhances ammonia detoxification, by stimulating the urea cycle and glutamine synthesis in the liver and muscles. This leads to a rapid reduction of elevated ammonia levels, improving neurological symptoms such as confusion, reduced consciousness, and cognitive impairment. In hospital and ICU settings, IV administration ensures fast and reliable effect, which is critical in acute hepatic encephalopathy. LOLA is well tolerated and can be used as part of comprehensive liver support therapy. It plays an important role in stabilizing patients and preventing progression of encephalopathy.